AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03095105
Drug: 200 mg BIA 6-512
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
Trial: NCT01962454
Drug: Placebo to match testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
Trial: NCT03279237
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: May help shrink tumor before surgery.
Trial: NCT00338936
Drug: Valsartan + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03125642
Drug: AraC
RxNorm normalized name: Carac
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
Trial: NCT03125642
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6
Trial: NCT01381523
Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
RxNorm normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
Trial: NCT01381523
Drug: Single-entity oral triptans
RxNorm normalized name: Ajuga reptans whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
Trial: NCT04727112
Drug: Usual care versus primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT study
Trial: NCT00100555
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00215501
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally twice a day for 14 days (dosage will vary)
Trial: NCT00120393
Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
Trial: NCT01219738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single inhaled dose of placebo from a DPI.
Trial: NCT03274700
Drug: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
Trial: NCT02162810
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
Trial: NCT02162810
Drug: placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
Trial: NCT05506371
Drug: No interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostocs to confirm the healthy state of the gingiva
Trial: NCT00243893
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Trial: NCT00243893
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Trial: NCT01954628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT02241018
Drug: calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02718846
Drug: Meniace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of Meniace tablets were administered 3 times per day after meals
Trial: NCT02718846
Drug: Isobide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
Trial: NCT01853124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
Trial: NCT01853124
Drug: Lacidofil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
Trial: NCT00318708
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500 mg twice daily (Biaxin)
Trial: NCT00318708
Drug: placebo clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo clarithromycin twice daily
Trial: NCT01538173
Drug: 250ml HES 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application twice a day 250ml HES 6% for three days postoperatively.
Trial: NCT01538173
Drug: 9% NaCl 500ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application twice a day 500ml 9% NaCl for three days postoperatively.
Trial: NCT03342443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
Trial: NCT00401583
Drug: GW786034 (pazopanib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
Trial: NCT02884115
Drug: benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00330824
Drug: antibiotic/steroid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1gtt, 4x/d, 15 days
Trial: NCT04544956
Drug: GSK3228836
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
Trial: NCT03029403
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
Trial: NCT04351152
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
Trial: NCT03522662
Drug: GSK1070806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10mg/kg infusion on Day 0
Trial: NCT01197040
Drug: acid mycophenolic (Myfortic)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
Trial: NCT03251469
Drug: Normal Saline, 100mg, iv, Singe dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Trial: NCT00851110
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
Trial: NCT03935646
Drug: Adderall IR 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
Trial: NCT03935646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00414440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT02291380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
Trial: NCT00002993
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00539786
Drug: Proton pump inhibitor (rabeprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
Trial: NCT01692704
Drug: Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
RxNorm normalized name: floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications.
Trial: NCT04382651
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Trial: NCT00004048
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04222725
Drug: TRS01 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed 4 times a day (QID)
Trial: NCT04222725
Drug: TRS01 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed QID
Trial: NCT04222725
Drug: Placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed QID
Trial: NCT01801397
Drug: osteoanabolic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02018250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
Trial: NCT02277132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets three times daily orally from randomization until delivery
Trial: NCT01910506
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03291379
Drug: BTG-002814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTG-002814 containing 100 mg vandetanib
Trial: NCT00607750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eyedrops, BID, 48 weeks
Trial: NCT01634347
Drug: Placebo and memory reactivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
Trial: NCT01172171
Drug: Melatonin, N-acetyl-5-methoxytryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
Trial: NCT01172171
Drug: Isotonic saline, Natrium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
Trial: NCT00477451
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Alprazolam Placebo
Trial: NCT00759473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00581607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: NCT00581607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01563835
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
Trial: NCT00745316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo - 2 capsules bid
Trial: NCT01914718
Drug: DA-EPOCH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
Trial: NCT03619785
Drug: Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or IV pain medication as needed.
Trial: NCT03322137
Drug: SNA-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegcantratinib ointment
Trial: NCT03322137
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment to mimic Pegcantratinib ointment
Trial: NCT03429556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
Trial: NCT01460836
Drug: Tobramycin solution for inhalation
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01460836
Drug: Aztreonam lysine for inhalation
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00501605
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003270
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01855789
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
Trial: NCT01855789
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO matching to MTX will be administered orally.
Trial: NCT02369510
Drug: Low-dose epinephrine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
Trial: NCT02369510
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
Trial: NCT02369510
Drug: No epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2ml of preservative-free saline will be added to the standard spinal medications
Trial: NCT06209957
Drug: Local corticosteroid injection
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
Trial: NCT01418222
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01418222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT01418222
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00677144
Drug: XELOX (oxalipaltin+capecitabine)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Trial: NCT03103750
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three 0.5 mcg capsules
Trial: NCT03604614
Drug: Without Hyperthermic Intraperitoneal Chemotherapy
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
Trial: NCT03461692
Drug: patients under 14 years of age using Reduning injeciton
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
Trial: NCT03340805
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.
Trial: NCT01962636
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
Trial: NCT01962636
Drug: Mycophenylate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
Trial: NCT04056130
Drug: KBL697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral
Trial: NCT00340327
Drug: IMA-638
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02112448
Drug: continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
Trial: NCT02112448
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be given every 4 hours for a total of 24 hours.
Trial: NCT02112448
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
Trial: NCT00210561
Drug: tramadol hydrochloride , acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495077
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form